Evidence map›Paper›PMID 36737752›Full record

ArticleJournal of translational medicine2023

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.

Pier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Valenca Bueno, Livia Maria Q S Andrade, Anna Patrikidou and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 5 countries.

Pier Vitale NuzzoDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Filippo PederzoliDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Calogero SaievaCancer Risk Factors and Lifestyle Epidemiology Unit-ISPRO, Florence, Italy.
Elisa ZanardiMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Giuseppe FotiaMedical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Andrea MalgeriDivision of Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Sabrina RossettiDepartment of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
Loana Valenca BuenoInstituto D'Or de Pesquisa e Ensino, Salvador, State of Bahia, Brazil.
Livia Maria Q S AndradeInstituto D'Or de Pesquisa e Ensino, Salvador, State of Bahia, Brazil.
Anna PatrikidouDepartment of Medical Oncology, Gustave Roussy Institute, Villejuif, France.
Ricardo Pereira MestreIstituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.
Mikol ModestiIstituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.
Sandro PignataDepartment of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
Giuseppe ProcopioOncology Unit, ASST Cremona, Cremona, CR, Italy.
Giuseppe FornariniMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Ugo De GiorgiDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy.
Antonio RussoDepartment of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.
Edoardo FranciniDepartment of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, Italy. edoardo.francini@unifi.it.ORCID 0000-0003-4270-7023
SPARTACUSS Investigators
Cornell University · USD’Or Institute for Research and Education · BRIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITOspedale Policlinico San Martino · ITUniversità della Svizzera italiana · CHCampus Bio Medico University Hospital · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITInstitut Gustave Roussy · FRIstituti Ospitalieri di Cremona · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITPiedmont Reference Center for Epidemiology and Cancer Prevention · ITUniversity of Florence · ITUniversity of Palermo · IT

Funding

Weill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUDAS, LORRAINE J · 2017 to 2021
$10.9M
NCI NIH HHS P50 CA211024
6 · The paper itself

Abstract

backgroundMetastatic castration-resistant prostate cancer remains a challenging condition to treat. Among the available therapeutic options, the androgen receptor signaling inhibitors abiraterone acetate plus prednisone (AA) and enzalutamide (Enza), are currently the most used first-line therapies in clinical practice. However, validated clinical indicators of prognosis in this setting are still lacking. In this study, we aimed to evaluate a prognostic model based on the time of metastatic disease presentation (after prior local therapy [PLT] or de-novo [DN]) and disease burden (low volume [LV] or high-volume [HV]) at AA/Enza onset for mCRPC patients receiving either AA or Enza as first-line.

methodsA cohort of consecutive patients who started AA or Enza as first-line treatment for mCRPC between January 1st, 2015, and April 1st, 2019 was identified from the clinical and electronic registries of the 9 American and European participating centers. Patients were classified into 4 cohorts by the time of metastatic disease presentation (PLT or DN) and volume of disease (LV or HV; per the E3805 trial, HV was defined as the presence of visceral metastases and/or at least 4 bone metastases of which at least 1 out the axial/pelvic skeleton) at AA/Enza onset. The endpoint was overall survival defined as the time from AA or Enza initiation, respectively, to death from any cause or censored at the last follow-up visit, whichever occurred first.

resultsOf the 417 eligible patients identified, 157 (37.6%) had LV/PLT, 87 (20.9%) LV/DN, 64 (15.3%) HV/PLT, and 109 (26.1%) HV/DN. LV cohorts showed improved median overall survival (59.0 months; 95% CI, 51.0-66.9 months) vs. HV cohorts (27.5 months; 95% CI, 22.8-32.2 months; P = 0.0001), regardless of the time of metastatic presentation. In multivariate analysis, HV cohorts were confirmed associated with worse prognosis compared to those with LV (HV/PLT, HR = 1.87; p = 0.029; HV/DN, HR = 2.19; P = 0.002).

conclusionOur analysis suggests that the volume of disease could be a prognostic factor for patients starting AA or Enza as first-line treatment for metastatic castration-resistant prostate cancer, pending prospective clinical trial validation.

Indexed as

Abiraterone AcetateProstatic Neoplasms, Castration-ResistantAntineoplastic Combined Chemotherapy ProtocolsBenzamidesHumansMaleNitrilesPhenylthiohydantoinPrednisoneProspective StudiesTreatment OutcomeAbiraterone AcetateBenzamidesenzalutamideNitrilesPhenylthiohydantoinPrednisoneAbiraterone acetateAndrogen receptor pathway inhibitorsEnzalutamideMetachronous metastasesMetastatic castration-resistant prostate cancerPrognostic factorSynchronous metastasesVolume of disease

Identifiers

PMID36737752
PMCPMC9896712
OpenAlexW4319080293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.